Telephone: 720-848-0852; FAX: 720-848-0833
Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal†
Article first published online: 28 AUG 2008
Copyright © 2008 American Association for the Study of Liver Diseases
Volume 14, Issue 9, pages 1281–1286, September 2008
How to Cite
Campsen, J., Zimmerman, M. A., Trotter, J. F., Wachs, M., Bak, T., Steinberg, T., Kaplan, M., Wright, F. and Kam, I. (2008), Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl, 14: 1281–1286. doi: 10.1002/lt.21525
This study was presented in part at the American Association for the Study of Liver Diseases meeting in Boston, MA, 2007.
- Issue published online: 28 AUG 2008
- Article first published online: 28 AUG 2008
- Manuscript Accepted: 26 FEB 2008
- Manuscript Received: 7 NOV 2007
Our center has attempted to minimize corticosteroid (CS) use in all of our orthotopic liver transplantation (OLT) recipients. Because patients with autoimmune hepatitis (AIH) typically require CSs after transplantation, we reviewed our experience in this cohort of patients to determine (1) patient outcomes including recurrent disease and (2) long-term requirements for CS use in AIH patients. From 1988 to 2006, 1102 OLTs were performed in 1032 adult patients at the University of Colorado, of whom 66 (6%) with AIH received 68 allografts. Recurrence was defined by a clinically worsening examination and histological evidence from biopsy. Bivariate and multivariate analyses were used to evaluate predictors of CS withdrawal. Twelve potential predictors of CS discontinuation were considered: age, gender, presence of inflammatory bowel disease (IBD), type of graft (cadaver or living donor), recurrence of AIH, warm ischemia time, follow-up time (time since transplant), and immunosuppressants (cyclosporine, tacrolimus, sirolimus, azathioprine, and mycophenolate mofetil). Overall survival at 5 years was 91%. The 1- and 5-year recurrence-free survival was 88% and 59%, respectively. Risk (incidence) of recurrent AIH at 1, 3, and 5 years was 12%, 26%, and 36%, respectively. Disease recurred in 23 of 66 patients or 34.8%. Of the 23 patients who developed recurrent disease, none received a second transplant because of recurrent disease. CSs were withdrawn in 50% of patients at the time of review. Only 2 factors on multivariate analysis were strongly associated negatively with CS withdrawal: (1) an increasing dose of the immunosuppressant and (2) the presence of IBD. Controlling for these other factors, we found that recurrent disease did not strongly influence CS withdrawal. In conclusion, outcomes in AIH patients were quite favorable, and none of the patients required retransplantation for recurrent AIH. With a CS minimization approach, one-half of the patients were able to remain CS-free. Liver Transpl 14:1281–1286, 2008. © 2008 AASLD.